EVscale™ is a sponsor of the event, with its three Austrian sister companies, Evercyte, Phoenestra, and TAmiRNA exhibiting at the event and contributing numerous scientific posters to the conference program.
ISEV 2025 team
ISEV annual meetings have repeatedly provided Evercyte with a scientific platform from which to share knowledge and its latest advances in EV technology, with its co-founders, Assoc. Prof. Dr. Johannes and Dr. Regina Grillari, widely recognized as leading authorities in exosome research. Dr. Regina Grillari, as Evercyte COO and joint CSO, will form part of the EVscale™ team at the 2025 conference, along with Phoenestra’s and TAmiRNA’s teams.
The three partner companies will share a stand at Booth B13 at the VIECON expo center, with displays showing how the EVscale™ platform combines their respective expertise areas to offer a one-stop solution for EV production, scale up and characterization. The service can be provided for individual aspects of EV manufacturing as well as a full-service end-to-end solution.
Combined EV expertise
Evercyte contributes its extensive ‘cell factory’ portfolio of telomerized MSC derived from different tissues (adipose tissue, bone-marrow, placenta, umbilical cord, etc.) to produce clinical-grade EVs. These cell lines have been established under xeno-free conditions, with full documentation of any manipulation step and therefore GMP-transfer ready.
Phoenestra specializes in scalable manufacturing of EV based on stable cell lines, performing cell cultivation in a fully controlled perfusion bioreactor system and isolation and purification of EV preparation with modular processing unit operations.
TAmiRNA’s role in EVscale™ is to provide unique EV characterization services, specifically transcriptomic analyses of both small (microRNAs) and larger (mRNA, long non-coding RNA) RNAs.
Poster presentations
The partners will make a series of scientific poster presentations to the meeting over two days.
On the opening day, Evercyte COO Dr. Regina Grillari will present a poster on ‘Telomerized MSCs of various tissues and donors: designer cell factories for standardizable and scalable production of clinical-grade EVs’ (Thursday, April 24, 2025 1230-1430 hrs. CET).
Evercyte R&D scientists Dr. Marieke Roefs and Johanna Gamauf will respectively contribute posters on ‘Rapid EV surface decoration with targeting moieties based on a FITC binding single chain antibody snorkel’ and ‘Clinical-grade extracellular vesicles isolated from telomerized mesenchymal stromal cells maintain biological activity over time’.
On the same day Magdalena Mecking from TAmiRNA will present a poster showing how ’Small RNA-sequencing (miND) enables discovery of EV-specific microRNA signatures that support EV drug development’.
Three Phoenestra leaders will also present posters on Day One, with CEO Dr. Klaus Graumann showing how ‘EV preparations from telomerized Mesenchymal Stromal Cell lines elicit robust performance in therapeutically relevant models,’ Melanie Reininger contributing’ Know Your Vesicles: How Cell Source Shapes Extracellular Vesicle Attributes’, and Dr. Roland Prielhofer presenting: ‘From Variability to Consistency: A Scalable Manufacturing System for Standardized Extracellular Vesicles from telomerized human Mesenchymal Stromal Cells.
On the following day, Evercyte doctoral candidate Alessia Brancolini will present a poster on ‘Lifespan extension of human MSCs with hTERT does not change the functional properties of cells and secreted EVs’ (Friday, April 25, 2025 16:30 – 17:30 hrs. CET).
Dr. Regina Grillari commented: “Through our booth and poster presentations we aim to network at ISEV 2025 with representatives from academia and industry who are working on applications of EVs as therapies.”
“We also hope to communicate our ultimate EVscale™ vision for an innovative one-stop shop and end-to-end platform for scalable and efficient manufacturing of extracellular vesicles from MSCs that will allow customers to tailor projects from cell sourcing to basic EV characterization, and from EV manufacturing to linking EV biological functions to RNA and protein EV components using TAmiRNA’s multiomics profiling services. Cells can then be adapted to tailored and scalable EV production, using Phoenestra’s proprietary fully controlled bioreactor,” Dr. Grillari explained.
About Evercyte GmbH
Evercyte is the leading provider of immortalized human primary-like cells (telomerized cells) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.
By providing native extracellular vesicles from mesenchymal stromal cells, Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com
About ISEV 2025
The International Society for Extracellular Vesicles is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes, with hundreds of members worldwide dedicated to advancing the study of extracellular vesicles globally.
Founded in 2012 in Sweden, ISEV is now headquartered in the USA. Through its programs and services, it provides essential training and research opportunities for those involved in exosome and microvesicle research.
The ISEV Annual Meeting attracts some 1,000 attendees, including top researchers in the field discussing the latest in extracellular vesicles, exosomes, and microvesicles.
ISEV 2025 is a five-day event, opening with an Education Day on April 23, followed by four conference days at the VIECON Convention Center in Vienna.
The event is organized by the International Society of Extracellular Vesicles with further information at: https://isev2025.eventscribe.net/
Resources
Click on Evercyte Cell Factories for EVs to learn more.
Click on Evercyte off-the shelf-EVs for further information.
Click on Phoenestra bioprocessing of stem cell lines for further information.